Attention, Solazyme Investors: Don't Forget About Amyris
Synthetic biology pioneer Amyris discussed its full-year 2013 results after market close. Here's what investors need to know about 2013 and what you can expect from operations in 2014.
How Solazyme, Inc. and Amyris, Inc. Bring Stability to a Risky World
Droughts and concerns of deforestation have ripped streaks of volatility through numerous raw materials that go into everyday products. Solazyme and Amyris are about to change that.
Big Companies Are Buying Into Biofuels
Big oil and chemical companies have financial resources and established infrastructure that is, at this point, unavailable to smaller biofuel companies. In the world of biofuels, maybe size does matter.
Solazyme, Inc. and Amyris, Inc. Will Make Sluggish Economic Growth a Distant Memory
The stock market holds its breath with every monthly economic report, but it seems to be ignoring a section of the economy that accounted for 7% of all GDP growth in 2011 and 2012. What is it, and how are Solazyme and Amyris driving it higher?